# C_2005209EN.01000301.xml

| 26.8.2005 | EN | Official Journal of the European Union | C 209/3 |
| --- | --- | --- | --- |

26.8.2005

EN

Official Journal of the European Union

C 209/3

---

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 July 2005 to 31 July 2005

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93 (1))

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93 (1

(2005/C 209/03)

—   Modification of a marketing authorization (Article 12 of Council Regulation (EEC) No 2309/93): Accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 4.7.2005 | Apidra | Aventis Pharma Deutschland GmbH, Brueningstrasse 50, D-65926 Frankfurt am Main | EU/1/04/285/001-028 | 6.7.2005 |
| 4.7.2005 | Forcaltonin | Unigene UK Limited, 63 High Road, Bushey Heath, Herts, WD2 1EE, United Kingdom | EU/1/98/093/002 | 6.7.2005 |
| 4.7.2005 | Trisenox | Cell Therapeutics (UK) Ltd, 100 Pall Mall, London SW1Y 5HP, United Kingdom | EU/1/02/204/001 | 6.7.2005 |
| 4.7.2005 | Levemir | Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd | EU/1/04/278/001-009 | 6.7.2005 |
| 4.7.2005 | Zerene | Wyeth Research (UK) Limited, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom | EU/1/99/099/001-006 | 6.7.2005 |
| 4.7.2005 | Sonata | Wyeth Europa Limited, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom | EU/1/99/102/001-008 | 6.7.2005 |
| 4.7.2005 | Cymbalta | Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, Nederland | EU/1/04/296/001-006 | 6.7.2005 |
| 4.7.2005 | Cymbalta | Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, Nederland | EU/1/04/296/001-006 | 6.7.2005 |
| 4.7.2005 | Xeristar | Boehringer Ingelheim International GmbH, Binger Strasse 173 — D-55216 Ingelheim am Rhein | EU/1/04/297/001-006 | 6.7.2005 |
| 4.7.2005 | Xeristar | Boehringer Ingelheim International GmbH, Binger Strasse 173 — D-55216 Ingelheim am Rhein | EU/1/04/297/001-006 | 6.7.2005 |
| 4.7.2005 | Visudyne | Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom | EU/1/00/140/001 | 6.7.2005 |
| 4.7.2005 | Xigris | Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, Nederland | EU/1/02/225/001-002 | 6.7.2005 |
| 7.7.2005 | Invanz | Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom | EU/1/02/216/001-002 | 11.7.2005 |
| 7.7.2005 | Arixtra | Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom | EU/1/02/206/001-008 | 11.7.2005 |
| 7.7.2005 | Quixidar | Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom | EU/1/02/207/001-008 | 11.7.2005 |
| 7.7.2005 | Cystagon | Orphan Europe, Immeuble ‘Le Guillaumet’, F-92046 Paris La Défense | EU/1/97/039/001-004 | 11.7.2005 |
| 8.7.2005 | Glivec | Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom | EU/1/01/198/001-013 | 12.7.2005 |
| 8.7.2005 | Aranesp | Amgen Europe BV, Minervum 7061, 4817 ZK Breda, Nederland | EU/1/01/185/001-056 | 12.7.2005 |
| 8.7.2005 | Nespo | Dompé Biotec SpA, Via San Martino, 12, I-20122 Milano | EU/1/01/184/001-056 | 12.7.2005 |
| 8.7.2005 | Lyrica | PFIZER Ltd, Ramsgate Road, Sandwich, Kent CT 13 9NJ, United Kingdom | EU/1/04/279/030-032 | 12.7.2005 |
| 8.7.2005 | Fortovase | Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom | EU/1/98/075/001-002 | 12.7.2005 |
| 8.7.2005 | AVANDIA | SmithKline Beecham plc, 980 Great West Road, Brentford, Middlesex, TW8 9GS United Kingdom | EU/1/00/137/001-012 | 12.7.2005 |
| 8.7.2005 | NovoRapid | Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd | EU/1/99/119/003
  EU/1/99/119/005-007
  EU/1/99/119/009-014 | 12.7.2005 |
| 8.7.2005 | NeuroBloc | Elan Pharma International Ltd., WIL House, Shannon Business Park, Shannon, County Clare, Ireland | EU/1/00/166/001-003 | 13.7.2005 |
| 8.7.2005 | Simulect | Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom | EU/1/98/084/001-002 | 12.7.2005 |
| 8.7.2005 | Zevalin | Schering AG, Müllerstrasse 170-178, D-13342 Berlin | EU/1/03/264/001 | 12.7.2005 |
| 8.7.2005 | Viread | Gilead Sciences International Limited, Cambridge CB1 6GT United Kingdom | EU/1/01/200/001 | 12.7.2005 |
| 8.7.2005 | Keppra | UCB SA, Allée de la recherche, 60, B-1070 Bruxelles/Researchdreef, 60, B-1070 Brussel | EU/1/00/146/001-027 | 12.7.2005 |
| 8.7.2005 | Lantus | Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main | EU/1/00/134/001-029 | 12.7.2005 |
| 8.7.2005 | Optisulin | Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main | EU/1/00/133/001-008 | 12.7.2005 |
| 13.7.2005 | NeoRecormon | Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom | EU/1/97/031/001-003
  EU/1/97/031/019-046 | 15.7.2005 |
| 22.7.2005 | Enbrel | Wyeth Europa Limited, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom | EU/1/99/126/001-011 | 26.7.2005 |
| 22.7.2005 | KOGENATE Bayer | Bayer AG, D-51368 Leverkusen | EU/1/00/143/001-006 | 26.7.2005 |
| 27.7.2005 | Vaniqa | Shire Pharmaceutical Contracts Ltd, Hampshire International Business Park, Chineham, Basingstoke, Hampshire RG24 8EP, United Kingdom | EU/1/01/173/001-003 | 29.7.2005 |
| 27.7.2005 | Infergen | Yamanouchi Europe B.V., Elisabethhof 19, 2353 EW Leiderdorp, Nederland | EU/1/98/087/001-003 | 29.7.2005 |
| 27.7.2005 | Zevalin | Schering AG, Müllerstrasse 170-178, D-13342 Berlin | EU/1/03/264/001 | 29.7.2005 |
| 27.7.2005 | Replagal | TKT Europe AB, Rinkebyvägen 11B, S-182 36 Danderyd | EU/1/01/189/001-006 | 29.7.2005 |
| 27.7.2005 | Velcade | Janssen-Cilag International NV, Turnhoutseweg, 30 B-2340 Beerse | EU/1/04/274/001 | 29.7.2005 |
| 27.7.2005 | AVANDIA | SmithKline Beecham plc, 980 Great West Road, Brentford, Middlesex, TW8 9GS United Kingdom | EU/1/00/137/001-012 | 29.7.2005 |
| 27.7.2005 | ReFacto | Wyeth Europa Ltd., Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom | EU/1/99/103/001-004 | 29.7.2005 |
| 28.7.2005 | Kineret | Amgen Europe BV, Minervum 7061, 4817 ZK Breda, Nederland | EU/1/02/203/001-004 | 1.8.2005 |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

4.7.2005

Apidra

Aventis Pharma Deutschland GmbH, Brueningstrasse 50, D-65926 Frankfurt am Main

EU/1/04/285/001-028

6.7.2005

4.7.2005

Forcaltonin

Unigene UK Limited, 63 High Road, Bushey Heath, Herts, WD2 1EE, United Kingdom

EU/1/98/093/002

6.7.2005

4.7.2005

Trisenox

Cell Therapeutics (UK) Ltd, 100 Pall Mall, London SW1Y 5HP, United Kingdom

EU/1/02/204/001

6.7.2005

4.7.2005

Levemir

Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd

EU/1/04/278/001-009

6.7.2005

4.7.2005

Zerene

Wyeth Research (UK) Limited, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom

EU/1/99/099/001-006

6.7.2005

4.7.2005

Sonata

Wyeth Europa Limited, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom

EU/1/99/102/001-008

6.7.2005

4.7.2005

Cymbalta

Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, Nederland

EU/1/04/296/001-006

6.7.2005

4.7.2005

Cymbalta

Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, Nederland

EU/1/04/296/001-006

6.7.2005

4.7.2005

Xeristar

Boehringer Ingelheim International GmbH, Binger Strasse 173 — D-55216 Ingelheim am Rhein

EU/1/04/297/001-006

6.7.2005

4.7.2005

Xeristar

Boehringer Ingelheim International GmbH, Binger Strasse 173 — D-55216 Ingelheim am Rhein

EU/1/04/297/001-006

6.7.2005

4.7.2005

Visudyne

Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom

EU/1/00/140/001

6.7.2005

4.7.2005

Xigris

Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, Nederland

EU/1/02/225/001-002

6.7.2005

7.7.2005

Invanz

Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom

EU/1/02/216/001-002

11.7.2005

7.7.2005

Arixtra

Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom

EU/1/02/206/001-008

11.7.2005

7.7.2005

Quixidar

Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom

EU/1/02/207/001-008

11.7.2005

7.7.2005

Cystagon

Orphan Europe, Immeuble ‘Le Guillaumet’, F-92046 Paris La Défense

EU/1/97/039/001-004

11.7.2005

8.7.2005

Glivec

Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom

EU/1/01/198/001-013

12.7.2005

8.7.2005

Aranesp

Amgen Europe BV, Minervum 7061, 4817 ZK Breda, Nederland

EU/1/01/185/001-056

12.7.2005

8.7.2005

Nespo

Dompé Biotec SpA, Via San Martino, 12, I-20122 Milano

EU/1/01/184/001-056

12.7.2005

8.7.2005

Lyrica

PFIZER Ltd, Ramsgate Road, Sandwich, Kent CT 13 9NJ, United Kingdom

EU/1/04/279/030-032

12.7.2005

8.7.2005

Fortovase

Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom

EU/1/98/075/001-002

12.7.2005

8.7.2005

AVANDIA

SmithKline Beecham plc, 980 Great West Road, Brentford, Middlesex, TW8 9GS United Kingdom

EU/1/00/137/001-012

12.7.2005

8.7.2005

NovoRapid

Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd

EU/1/99/119/003

EU/1/99/119/005-007

EU/1/99/119/009-014

12.7.2005

8.7.2005

NeuroBloc

Elan Pharma International Ltd., WIL House, Shannon Business Park, Shannon, County Clare, Ireland

EU/1/00/166/001-003

13.7.2005

8.7.2005

Simulect

Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom

EU/1/98/084/001-002

12.7.2005

8.7.2005

Zevalin

Schering AG, Müllerstrasse 170-178, D-13342 Berlin

EU/1/03/264/001

12.7.2005

8.7.2005

Viread

Gilead Sciences International Limited, Cambridge CB1 6GT United Kingdom

EU/1/01/200/001

12.7.2005

8.7.2005

Keppra

UCB SA, Allée de la recherche, 60, B-1070 Bruxelles/Researchdreef, 60, B-1070 Brussel

EU/1/00/146/001-027

12.7.2005

8.7.2005

Lantus

Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main

EU/1/00/134/001-029

12.7.2005

8.7.2005

Optisulin

Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main

EU/1/00/133/001-008

12.7.2005

13.7.2005

NeoRecormon

Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom

EU/1/97/031/001-003

EU/1/97/031/019-046

15.7.2005

22.7.2005

Enbrel

Wyeth Europa Limited, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom

EU/1/99/126/001-011

26.7.2005

22.7.2005

KOGENATE Bayer

Bayer AG, D-51368 Leverkusen

EU/1/00/143/001-006

26.7.2005

27.7.2005

Vaniqa

Shire Pharmaceutical Contracts Ltd, Hampshire International Business Park, Chineham, Basingstoke, Hampshire RG24 8EP, United Kingdom

EU/1/01/173/001-003

29.7.2005

27.7.2005

Infergen

Yamanouchi Europe B.V., Elisabethhof 19, 2353 EW Leiderdorp, Nederland

EU/1/98/087/001-003

29.7.2005

27.7.2005

Zevalin

Schering AG, Müllerstrasse 170-178, D-13342 Berlin

EU/1/03/264/001

29.7.2005

27.7.2005

Replagal

TKT Europe AB, Rinkebyvägen 11B, S-182 36 Danderyd

EU/1/01/189/001-006

29.7.2005

27.7.2005

Velcade

Janssen-Cilag International NV, Turnhoutseweg, 30 B-2340 Beerse

EU/1/04/274/001

29.7.2005

27.7.2005

AVANDIA

SmithKline Beecham plc, 980 Great West Road, Brentford, Middlesex, TW8 9GS United Kingdom

EU/1/00/137/001-012

29.7.2005

27.7.2005

ReFacto

Wyeth Europa Ltd., Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom

EU/1/99/103/001-004

29.7.2005

28.7.2005

Kineret

Amgen Europe BV, Minervum 7061, 4817 ZK Breda, Nederland

EU/1/02/203/001-004

1.8.2005

—   Issuing of a marketing authorization (Article 34 of Council Regulation (EEC) No 2309/93): Accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 8.7.2005 | Equilis Prequenza | Intervet International BV, Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland | EU/2/05/056/001-002 | 12.7.2005 |
| 8.7.2005 | Equilis Prequenza Te | Intervet International BV, Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland | EU/2/05/057/001-002 | 12.7.2005 |
| 8.7.2005 | Equilis Te | Intervet International BV, Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland | EU/2/05/055/001-002 | 12.7.2005 |
| 27.7.2005 | Profender | Bayer Healthcare AG, D-51368 Leverkusen | EU/2/05/054/001-017 | 29.7.2005 |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

8.7.2005

Equilis Prequenza

Intervet International BV, Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland

EU/2/05/056/001-002

12.7.2005

8.7.2005

Equilis Prequenza Te

Intervet International BV, Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland

EU/2/05/057/001-002

12.7.2005

8.7.2005

Equilis Te

Intervet International BV, Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland

EU/2/05/055/001-002

12.7.2005

27.7.2005

Profender

Bayer Healthcare AG, D-51368 Leverkusen

EU/2/05/054/001-017

29.7.2005

—   Modification of a marketing authorization (Article 34 of Council Regulation (EEC) No 2309/93): Accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 7.7.2005 | Neocolipor | Merial, 29 avenue Tony Garnier, F-69007 Lyon | EU/2/98/008/001-004 | 11.7.2005 |
| 8.7.2005 | Ibaflin | Intervet International BV, Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland | EU/2/00/022/001a-001b, 002a-002b, 003a-003b, 004a-004b,
  EU/2/00/022/005-017, | 12.7.2005 |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

7.7.2005

Neocolipor

Merial, 29 avenue Tony Garnier, F-69007 Lyon

EU/2/98/008/001-004

11.7.2005

8.7.2005

Ibaflin

Intervet International BV, Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland

EU/2/00/022/001a-001b, 002a-002b, 003a-003b, 004a-004b,

EU/2/00/022/005-017,

12.7.2005

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

| The European Medicines Agency |
| --- |
| 7, Westferry Circus, Canary Wharf |
| London E14 4HB |
| United Kingdom |

The European Medicines Agency

7, Westferry Circus, Canary Wharf

London E14 4HB

United Kingdom

---

(1)  OJ L 214 of 24.8.1993, p. 1.

1

---